Detailed information for compound 106004
Basic information
Technical information
- Name: Unnamed compound
- MW: 445.941 | Formula: C26H24ClN3O2
-
H donors: 0
H acceptors: 3
LogP: 2.65
Rotable bonds: 3
Rule of 5 violations (Lipinski): 1 - SMILES: [O-][n+]1ccc(cc1)CC(=O)N1CCC(=C2c3ccc(cc3CCc3c2nccc3)Cl)CC1
- InChi: 1S/C26H24ClN3O2/c27-22-5-6-23-21(17-22)4-3-20-2-1-11-28-26(20)25(23)19-9-12-29(13-10-19)24(31)16-18-7-14-30(32)15-8-18/h1-2,5-8,11,14-15,17H,3-4,9-10,12-13,16H2
- InChiKey: SQAJXBGZLZTIBS-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | farnesyltransferase, CAAX box, alpha | Starlite/ChEMBL | References |
| Homo sapiens | farnesyltransferase, CAAX box, beta | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| AUC (ADMET) | = 5 ug hr ml-1 | Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice | ChEMBL. | 9435898 |
| AUC (ADMET) | = 5 ug hr ml-1 | Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice | ChEMBL. | 9435898 |
| AUC (ADMET) | = 11.9 ug hr ml-1 | Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice | ChEMBL. | 9435898 |
| AUC (ADMET) | = 11.9 ug hr ml-1 | Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice | ChEMBL. | 9435898 |
| Cmax (ADMET) | = 8 ug ml-1 | Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice | ChEMBL. | 9435898 |
| Cmax (ADMET) | = 8 ug ml-1 | Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice | ChEMBL. | 9435898 |
| IC50 (binding) | = 530 nM | Inhibition of Farnesyl protein transferase | ChEMBL. | 10377218 |
| IC50 (binding) | = 530 nM | Inhibition of Farnesyl protein transferase | ChEMBL. | 10377218 |
| IC50 (binding) | = 0.53 uM | Compound was tested for the inhibition of Farnesyltransferase | ChEMBL. | 9435898 |
| IC50 (binding) | = 0.53 uM | Inhibitory activity against recombinant human farnesyltransferase | ChEMBL. | 9406600 |
| IC50 (binding) | = 0.53 uM | Compound was tested for the inhibition of Farnesyltransferase | ChEMBL. | 9435898 |
| IC50 (binding) | = 0.53 uM | Inhibitory activity against recombinant human farnesyltransferase | ChEMBL. | 9406600 |
| IC50 (functional) | = 1 uM | Compound was tested for the inhibition of COS cells in monkey. | ChEMBL. | 9435898 |
| Kd | = 240 nM | Dissociation constant of the Compound | ChEMBL. | 10377218 |
| T1/2 (ADMET) | = 76 min | half life period of the compound is evaluated by administering intravenously at 25 mg/kg in mice | ChEMBL. | 9435898 |
| T1/2 (ADMET) | = 76 min | half life period of the compound is evaluated by administering intravenously at 25 mg/kg in mice | ChEMBL. | 9435898 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL63804
- PubChem: 10575347
Bibliographic References
3 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.